Loading
Growing a patient's own tumour-fighting cells only works if those cells are there to start with. A test for them would spare futile treatment.
Tumour-infiltrating lymphocyte therapy is approved in melanoma but works in a minority, and manufacturing takes weeks and costs a great deal. Markers of genuinely tumour-reactive T cells, notably CD39 and CD69 co-expression and CXCL13 expression, distinguish reactive from bystander cells in human tumours. A pre-manufacture biopsy assay could predict product potency and patient benefit.
Shares Ton Schumacher, John Haanen, Lifileucel, Tumour-infiltrating lymphocytes (TILs).
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy, Melanoma.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy, Manufacturing cost and time for living and radioactive medicines.
Shares Iovance Biotherapeutics, Lifileucel, Tumour-infiltrating lymphocytes (TILs), TIL therapy.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy, Melanoma.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, No one can predict who responds to immunotherapy.
Shares Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised.